Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Ascending, Open Phase I Clinical Study to Evaluate the Safety, Tolerability , Pharmacokinetics Characteristics and Preliminary Effectiveness of VG161 in Subjects with Advanced Primary Liver Cancer

NCT04806464 is registered in ClinicalTrials.gov with CNBG-Virogin Biotech (Shanghai) Ltd. as lead sponsor.

NCT NCT04806464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04806464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Ascending, Open Phase I Clinical Study to Evaluate the Safety, Tolerability , Pharmacokinetics Characteristics and Preliminary Effectiveness of VG161 in Subjects with Advanced Primary Liver Cancer
Lead sponsor
CNBG-Virogin Biotech (Shanghai) Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 16, 2021
Completion date
December 31, 2024
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary liver cancer